keyword
MENU ▼
Read by QxMD icon Read
search

vaccine adjuvants

keyword
https://www.readbyqxmd.com/read/28522873/recombinant-bcg-expressing-ltak63-adjuvant-induces-superior-protection-against-mycobacterium-tuberculosis
#1
Ivan P Nascimento, Dunia Rodriguez, Carina C Santos, Eduardo P Amaral, Henrique K Rofatto, Ana P Junqueira-Kipnis, Eduardo D C Gonçalves, Maria R D'Império-Lima, Mario H Hirata, Celio L Silva, Nathalie Winter, Brigitte Gicquel, Kingston H G Mills, Mariagrazia Pizza, Rino Rappuoli, Luciana C C Leite
In order to develop an improved BCG vaccine against tuberculosis we have taken advantage of the adjuvant properties of a non-toxic derivative of Escherichia coli heat labile enterotoxin (LT), LTAK63. We have constructed rBCG strains expressing LTAK63 at different expression levels. Mice immunized with BCG expressing low levels of LTAK63 (rBCG-LTAK63lo) showed higher Th1 cytokines and IL-17 in the lungs, and when challenged intratracheally with Mycobacterium tuberculosis displayed a 2.0-3.0 log reduction in CFU as compared to wild type BCG...
May 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28522427/association-of-chitosan-and-aluminium-as-a-new-adjuvant-strategy-for-improved-vaccination
#2
F Lebre, D Bento, J Ribeiro, M Colaço, G Borchard, M C Pedroso de Lima, O Borges
The use of particulate adjuvants offers an interesting possibility to enhance and modulate the immune responses elicited by vaccines. Aluminium salts have been extensively used as vaccine adjuvants, but they lack the capacity to induce a strong cellular and mucosal immune response. Taking this into consideration, in this study we designed a new antigen delivery system combining aluminium salts with chitosan. Chitosan-aluminium nanoparticles (CH-Al NPs) exhibited a mean diameter of 280nm and a positive surface charge...
May 15, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28522213/harnessing-self-assembled-peptide-nanoparticles-in-epitope-vaccine-design
#3
REVIEW
Manica Negahdaripour, Nasim Golkar, Nasim Hajighahramani, Sedigheh Kianpour, Navid Nezafat, Younes Ghasemi
Vaccination has been one of the most successful breakthroughs in medical history. In recent years, epitope-based subunit vaccines have been introduced as a safer alternative to traditional vaccines. However, they suffer from limited immunogenicity. Nanotechnology has shown value in solving this issue. Different kinds of nanovaccines have been employed, among which virus-like nanoparticles (VLPs) and self-assembled peptide nanoparticles (SAPNs) seem very promising. Recently, SAPNs have attracted special interest due to their unique properties, including molecular specificity, biodegradability, and biocompatibility...
May 15, 2017: Biotechnology Advances
https://www.readbyqxmd.com/read/28522212/bioengineering-bacterial-outer-membrane-vesicles-as-vaccine-platform
#4
REVIEW
Matthias J H Gerritzen, Dirk E Martens, René H Wijffels, Leo van der Pol, Michiel Stork
Outer membrane vesicles (OMVs) are naturally non-replicating, highly immunogenic spherical nanoparticles derived from Gram-negative bacteria. OMVs from pathogenic bacteria have been successfully used as vaccines against bacterial meningitis and sepsis among others and the composition of the vesicles can easily be engineered. OMVs can be used as a vaccine platform by engineering heterologous antigens to the vesicles. The major advantages of adding heterologous proteins to the OMV are that the antigens retain their native conformation, the ability of targeting specific immune responses, and a single production process suffices for many vaccines...
May 15, 2017: Biotechnology Advances
https://www.readbyqxmd.com/read/28516859/recombinant-esterase-from-corynebacterium-pseudotuberculosis-in-dna-and-subunit-recombinant-vaccines-partially-protects-mice-against-challenge
#5
Alexandre Antunes Brum, Andrea de Fatima Silva Rezende, Francisco Silvestre Brilhante, Thais Collares, Karine Begnine, Fabiana Kommling Seixas, Tiago Veiras Collares, Odir Antônio Dellagostin, Vasco Azevedo, Anderson Santos, Ricardo Wagner Portela, Sibele Borsuk
PURPOSE: We tested the efficacy of the esterase encoded by cp1002_RS09720 from Corynebacteriumpseudotuberculosis in recombinant subunit and DNA caseous lymphadenitis (CLA) vaccines. This target was predicted as one of the best CLA vaccine candidates by mature epitope density analysis. METHODOLOGY: Gene cp1002_RS09720 was cloned into two different vectors (pAE for subunit vaccine and pTARGET for DNA vaccine). Four groups of 15 mice each were immunized with the recombinant esterase rCP09720 associated with aluminium hydroxide adjuvant (G1), pTARGET/cp09720 DNA vaccine (G2), a naked pTARGET (G3) or PBS as a negative control (G4)...
May 18, 2017: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/28516400/sytematic-investigation-of-the-role-of-surfactant-composition-and-choice-of-oil-design-of-a-nanoemulsion-based-adjuvant-inducing-concomitant-humoral-and-cd4-t-cell-responses
#6
Signe Tandrup Schmidt, Malene Aaby Neustrup, Stine Harloff-Helleberg, Karen Smith Korsholm, Thomas Rades, Peter Andersen, Dennis Christensen, Camilla Foged
PURPOSE: Induction of cell-mediated immune (CMI) responses is crucial for vaccine-mediated protection against difficult vaccine targets, e.g., Chlamydia trachomatis (Ct). Adjuvants are included in subunit vaccines to potentiate immune responses, but many marketed adjuvants stimulate predominantly humoral immune responses. Therefore, there is an unmet medical need for new adjuvants, which potentiate humoral and CMI responses. The purpose was to design an oil-in-water nanoemulsion adjuvant containing a synthetic CMI-inducing mycobacterial monomycoloyl glycerol (MMG) analogue to concomitantly induce humoral and CMI responses...
May 17, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28516208/safety-and-efficiency-of-active-immunization-with-detoxified-antigen-against-scorpion-venom-side-effect-evaluation
#7
Nassrine Bachsais, Lila Boussag-Abib, Fatima Laraba-Djebari
OBJECTIVE: The efficiency and safety of vaccine are the most important properties, however, as any medication, it can induce side effects. This prophylactic therapy could be used to prevent the lethal and pathophysiological effects induced after scorpion envenomation. METHODS: In this study, detoxified venom associated to alum adjuvant (V*alum) is used as a vaccine against scorpion venom for immunization of mice. We evaluate the safety and the inflammatory response of this vaccine...
May 17, 2017: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://www.readbyqxmd.com/read/28516165/host-and-pathogen-derived-adjuvant-coatings-on-protein-nanoparticle-vaccines
#8
Timothy Z Chang, Ishatou Diambou, Jong Rok Kim, Baozhong Wang, Julie A Champion
Nanoparticulate and molecular adjuvants have shown great efficacy in enhancing immune responses, and the immunogenic vaccines of the future will most likely contain both. To investigate the immunostimulatory effects of molecular adjuvants on nanoparticle vaccines, we have designed ovalbumin (OVA) protein nanoparticles coated with two different adjuvants-flagellin (FliC) and immunoglobulin M (IgM). These proteins, derived from Salmonella and mice, respectively, are representatives of pathogen- and host-derived molecules that can enhance immune responses...
March 2017: Bioengineering & Translational Medicine
https://www.readbyqxmd.com/read/28515938/accounting-for-adjuvant-induced-artifacts-in-the-characterization-of-vaccine-formulations-by-polyacrylamide-gel-electrophoresis
#9
Virginie Jakob, Livia Brunner, Christophe Barnier-Quer, Molly Blust, Nicolas Collin, Lauren Carter, Darrick Carter, Kelly M Rausch, Christopher B Fox
OBJECTIVES: Several vaccine adjuvants comprise complex nano- or micro-particle formulations, such as oil-in-water emulsions. In order to characterize interactions and compatibility of oil-in-water emulsion adjuvants with protein antigens in vaccines, effective protein characterization methods that can accommodate potential interference from high concentrations of lipid-based particles are needed. METHODS: Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a standard protein characterization technique which is affected by the presence of adjuvants such as oil-in-water emulsions...
April 2017: Therapeutic Advances in Vaccines
https://www.readbyqxmd.com/read/28515346/the-novel-complex-combination-of-alum-cpg-odn-and-hh2-as-adjuvant-in-cancer-vaccine-effectively-suppresses-tumor-growth-in-vivo
#10
Yaomei Tian, Meng Li, Chaoheng Yu, Rui Zhang, Xueyan Zhang, Rong Huang, Lian Lu, Fengjiao Yuan, Yingzi Fan, Bailing Zhou, Ke Men, Heng Xu, Li Yang
Single-component adjuvant is prone to eliciting a specific type of Th1 or Th2 response. So, the development of combinatorial adjuvants inducing a robust mixed Th1/Th2 response is a promising vaccination strategy against cancer. Here, we describe a novel combination of aluminum salts (alum), CpG oligodeoxynucleotide (CpG) and innate defense regulator peptide HH2 for improving anti-tumor immune responses. The CpG-HH2 complex significantly enhanced the production of IFN-γ, TNF-α and IL-1β, promoted the uptake of antigen and strengthened the activation of p38, Erk1/2 and NF-κB in vitro, compared to CpG or HH2 alone...
April 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28513561/the-effect-of-physicochemical-modification-on-the-function-of-antibodies-induced-by-anti-nicotine-vaccine-in-mice
#11
Jennifer M Thorn, Keshab Bhattacharya, Renata Crutcher, Justin Sperry, Colleen Isele, Barbara Kelly, Libbey Yates, James Zobel, Ningli Zhang, Heather L Davis, Michael J McCluskie
Smoking remains one of the major causes of morbidity and mortality worldwide. One approach to assisting smoking cessation is via anti-nicotine vaccines, composed of nicotine-like haptens conjugated to a carrier protein plus adjuvant(s). We have previously shown that the carrier, hapten, linker, hapten load, degree of conjugate aggregation, and presence of adducts can each influence the function (nicotine-binding capacity) of the antibody (Ab) induced. Herein, we extend those findings and show that tertiary structure is also critical to the induction of functional immune responses and that this can be influenced by conjugation conditions...
May 17, 2017: Vaccines
https://www.readbyqxmd.com/read/28511853/immunologic-evaluation-of-10-different-adjuvants-for-use-in-vaccines-for-chickens-against-highly-pathogenic-avian-influenza-virus
#12
Nazir Ahmed Lone, Erica Spackman, Darrell Kapczynski
Avian influenza viruses (AIV) are a threat to poultry production worldwide. Vaccination is utilized as a component of control programs for both high pathogenicity (HP) and low pathogenicity (LP) AIV. Over 95% of all AIV vaccine used in poultry are inactivated, adjuvanted products. To identify the best formulations for chickens, vaccines were prepared with beta-propiolactone (BPL) inactivated A/British Columbia/314514-1/2004 H7N3 LP AIV using ten commercially available or experimental adjuvants. Each vaccine formulation was evaluated for immunogenicity in chickens...
May 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28511142/tailoring-nanostructured-lipid-carriers-for-the-delivery-of-protein-antigens-physicochemical-properties-versus-immunogenicity-studies
#13
Thomas Courant, Emilie Bayon, Hei Lanne Reynaud-Dougier, Christian Villiers, Mathilde Menneteau, Patrice N Marche, Fabrice P Navarro
New vaccine formulations are still highly anticipated in the near-future to face incoming health challenges, such as emergence or reemergence of severe infectious diseases, immunosenescence associated with elderly or the spread of pathogens resistant to antibiotics. In particular, new nanoparticle-based adjuvants are promising for sub-unit vaccines in order to elicit potent and long lasting immune responses with a better control on their safety. In this context, an innovative delivery system of protein antigens has been designed based on the chemical grafting of the antigen onto the shell of Nanostructured Lipid Carriers (NLC)...
May 3, 2017: Biomaterials
https://www.readbyqxmd.com/read/28510418/conjugation-reaction-with-8-arm-peg-markedly-improves-the-immunogenicity-of-mycobacterium-tuberculosis-cfp10-tb10-4-fusion-protein
#14
Xiaowei Sun, Weili Yu, Quanhai Pang, Tao Hu
Mycobacterium tuberculosis (Mtb) is a serious fatal pathogen responsible for tuberculosis (TB). Effective vaccination is highly desired for immunoprotection against Mtb infection. CFP10 and TB10.4 are two important immunodominant Mtb-secreted protein antigens, which suffer from poor immunogenicity. Thus, an antigen delivery system and adjuvants are needed to improve the immunogenicity of the two proteins. CFP10 and TB10.4 are two Mtb-secreted immunodominant protein antigens. A CFP10-TB10.4 fusion protein (CT) was used as the antigen...
May 16, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28508938/immunotherapy-for-the-treatment-of-uveal-melanoma-current-status-and-emerging-therapies
#15
REVIEW
Kimberly M Komatsubara, Richard D Carvajal
PURPOSE OF REVIEW: Uveal melanoma is a distinct subset of melanoma with a biology and treatment approach that is unique from that of cutaneous melanoma. Here we will review the current data evaluating immunotherapies in both the adjuvant and metastatic settings in uveal melanoma. RECENT FINDINGS: In the adjuvant setting, interferon demonstrated no survival benefit in uveal melanoma, and studies evaluating immune-based strategies such as vaccine therapy are ongoing...
July 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28508465/proteomics-show-antigen-presentation-processes-in-human-immune-cells-after-as03-h5n1-vaccination
#16
Allison C Galassie, Johannes B Goll, Parimal Samir, Travis L Jensen, Kristen L Hoek, Leigh M Howard, Tara M Allos, Xinnan Niu, Laura E Gordy, C Buddy Creech, Heather Hill, Sebastian Joyce, Kathryn M Edwards, Andrew J Link
Adjuvants enhance immunity elicited by vaccines through mechanisms that are poorly understood. Using a systems biology approach, we investigated temporal protein expression changes in five primary human immune cell populations: neutrophils, monocytes, natural killer (NK) cells, T-cells, and B-cells after administration of either an Adjuvant System 03 (AS03)-adjuvanted or unadjuvanted split-virus H5N1 influenza vaccine. Monocytes demonstrated the strongest differential signal between vaccine groups. On day 3 post-vaccination, several antigen presentation-related pathways, including MHC class I-mediated antigen processing and presentation, were enriched in monocytes and neutrophils and expression of HLA Class I proteins was increased in the AS03 group...
May 15, 2017: Proteomics
https://www.readbyqxmd.com/read/28507029/cd63-mediated-antigen-delivery-into-extracellular-vesicles-via-dna-vaccination-results-in-robust-cd8-t-cell-responses
#17
Tomohiro Kanuma, Takuya Yamamoto, Kouji Kobiyama, Eiko Moriishi, Yuji Masuta, Takato Kusakabe, Koji Ozasa, Etsushi Kuroda, Nao Jounai, Ken J Ishii
DNA vaccines are attractive immunogens for priming humoral and cellular immune responses to the encoded Ag. However, their ability to induce Ag-specific CD8(+) T cell responses requires improvement. Among the strategies for improving DNA vaccine immunogenicity are booster vaccinations, alternate vaccine formulations, electroporation, and genetic adjuvants, but few, such as extracellular vesicles (EVs), target natural Ag delivery systems. By focusing on CD63, a tetraspanin protein expressed on various cellular membranes, including EVs, we examined whether a DNA vaccine encoding an Ag fused to CD63 delivered into EVs would improve vaccine immunogenicity...
May 15, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28506538/epitope-specific-immunotherapy-targeting-cd4-positive-t-cells-in-coeliac-disease-two-randomised-double-blind-placebo-controlled-phase-1-studies
#18
Gautam Goel, Tim King, A James Daveson, Jane M Andrews, Janakan Krishnarajah, Richard Krause, Gregor J E Brown, Ronald Fogel, Charles F Barish, Roger Epstein, Timothy P Kinney, Philip B Miner, Jason A Tye-Din, Adam Girardin, Juha Taavela, Alina Popp, John Sidney, Markku Mäki, Kaela E Goldstein, Patrick H Griffin, Suyue Wang, John L Dzuris, Leslie J Williams, Alessandro Sette, Ramnik J Xavier, Ludvig M Sollid, Bana Jabri, Robert P Anderson
BACKGROUND: A gluten-free diet is the only means to manage coeliac disease, a permanent immune intolerance to gluten. We developed a therapeutic vaccine, Nexvax2, designed to treat coeliac disease. Nexvax2 is an adjuvant-free mix of three peptides that include immunodominant epitopes for gluten-specific CD4-positive T cells. The vaccine is intended to engage and render gluten-specific CD4-positive T cells unresponsive to further antigenic stimulation. We assessed the safety and pharmacodynamics of the vaccine in patients with coeliac disease on a gluten-free diet...
May 11, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28505524/inactivated-influenza-virus-vaccines-the-future-of-tiv-and-qiv
#19
REVIEW
Michael Schotsaert, Adolfo García-Sastre
Influenza viruses continue to be a major public health concern, despite the availability of vaccines. Currently licensed influenza vaccines aim at the induction of antibodies that target hemagglutinin, the major antigenic determinant on the surface of influenza virions that is responsible for attachment of the virus to the host cell that is to be infected. Currently licensed influenza vaccines come as inactivated or live attenuated influenza vaccines and are trivalent or quadrivalent as they contain antigens of two influenza A and one or two influenza B strains that circulate in the human population, respectively...
May 12, 2017: Current Opinion in Virology
https://www.readbyqxmd.com/read/28505356/distinct-th1-and-th2-cellular-responses-associated-with-malaria-protection-and-risk-in-rts-s-as01e-vaccinees
#20
Gemma Moncunill, Maxmillian Mpina, Augusto J Nhabomba, Ruth Aguilar, Aintzane Ayestaran, Héctor Sanz, Joseph J Campo, Chenjerai Jairoce, Diana Barrios, Yan Dong, Núria Díez-Padrisa, José F Fernandes, Salim Abdulla, Jahit Sacarlal, Nana A Williams, Jaroslaw Harezlak, Benjamin Mordmüller, Selidji T Agnandji, John J Aponte, Claudia Daubenberger, Clarissa Valim, Carlota Dobaño
Background.: The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants than children. Current efforts to enhance RTS,S/AS01E efficacy would benefit from learning about the vaccine-induced immunity and identifying correlates of malaria protection, which could, for instance, inform the choice of adjuvants. Here, we sought cellular immunity-based correlates of malaria protection and risk associated with RTS,S/AS01E vaccination. Methods.: We performed a matched case-control study nested within the multicenter African RTS,S/AS01E Phase III trial...
May 13, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
12358
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"